Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast pediatric fibrosing interstitial lung disease study
2025-523369-32-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of nerandomilast in pulmonary fibrosis (PF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: AUCT,SS at steady state and Treatment-emergent adverse events through Week 26. Planned start Jul 2026; status: authorised.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2025-523369-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523369-32-00.